SE0401790D0 - Tamoxifen response in pre- and postmenopausal breast cancer patients - Google Patents
Tamoxifen response in pre- and postmenopausal breast cancer patientsInfo
- Publication number
- SE0401790D0 SE0401790D0 SE0401790A SE0401790A SE0401790D0 SE 0401790 D0 SE0401790 D0 SE 0401790D0 SE 0401790 A SE0401790 A SE 0401790A SE 0401790 A SE0401790 A SE 0401790A SE 0401790 D0 SE0401790 D0 SE 0401790D0
- Authority
- SE
- Sweden
- Prior art keywords
- breast cancer
- cancer patients
- postmenopausal breast
- tamoxifen response
- tamoxifen
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE0401790A SE0401790D0 (sv) | 2004-07-07 | 2004-07-07 | Tamoxifen response in pre- and postmenopausal breast cancer patients |
PCT/SE2005/001116 WO2006004545A1 (en) | 2004-07-07 | 2005-07-06 | Tamoxifen response in pre-and postmenopausal breast cancer patients |
EP05757471A EP1773309A1 (en) | 2004-07-07 | 2005-07-06 | Tamoxifen response in pre-and postmenopausal breast cancer patients |
US11/620,275 US20070213403A1 (en) | 2004-07-07 | 2007-01-05 | Tamoxifen response in pre-and postmenopausal breast cancer patients |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE0401790A SE0401790D0 (sv) | 2004-07-07 | 2004-07-07 | Tamoxifen response in pre- and postmenopausal breast cancer patients |
Publications (1)
Publication Number | Publication Date |
---|---|
SE0401790D0 true SE0401790D0 (sv) | 2004-07-07 |
Family
ID=32768801
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SE0401790A SE0401790D0 (sv) | 2004-07-07 | 2004-07-07 | Tamoxifen response in pre- and postmenopausal breast cancer patients |
Country Status (4)
Country | Link |
---|---|
US (1) | US20070213403A1 (sv) |
EP (1) | EP1773309A1 (sv) |
SE (1) | SE0401790D0 (sv) |
WO (1) | WO2006004545A1 (sv) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005118551A2 (en) | 2004-05-28 | 2005-12-15 | Ligand Pharmaceuticals Inc. | Thrombopoietin activity modulating compounds and methods |
JP4728340B2 (ja) | 2004-10-25 | 2011-07-20 | リガンド・ファーマシューティカルズ・インコーポレイテッド | トロンボポエチン活性を変調する化合物および変調方法 |
US20140018253A1 (en) * | 2012-04-05 | 2014-01-16 | Oregon Health And Science University | Gene expression panel for breast cancer prognosis |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3539588A (en) * | 1967-12-06 | 1970-11-10 | American Home Prod | Trans-1,4,4a,5,6,11b-hexahydro-11h-benzo(a) carbazol-5-one,thiosemicarbazones |
US4769378A (en) * | 1986-03-31 | 1988-09-06 | Eli Lilly And Company | Indenopyrimidine aromatase inhibitors |
US6982142B2 (en) * | 1997-12-01 | 2006-01-03 | John Wayne Cancer Institute | Methods for screening therapeutically effective agents |
WO2000034788A1 (en) * | 1998-12-08 | 2000-06-15 | Board Of Regents, The University Of Texas System | Methods for detection of antiestrogen-resistant breast cancer |
UA75054C2 (uk) * | 1999-10-13 | 2006-03-15 | Бьорінгер Інгельхайм Фарма Гмбх & Ко. Кг | Заміщені в положенні 6 індолінони, їх одержання та їх застосування як лікарського засобу |
ME00415B (me) * | 2000-02-15 | 2011-10-10 | Pharmacia & Upjohn Co Llc | Pirol supstituisani 2-indol protein kinazni inhibitori |
EP1330251A4 (en) * | 2000-10-06 | 2006-03-15 | Intarcia Therapeutics Inc | POLYTHERAPY FOR THE TREATMENT OF OESTROGENIC SENSITIVE DISEASE |
EP1458713B1 (en) * | 2001-12-27 | 2005-08-24 | Theravance, Inc. | Indolinone derivatives useful as protein kinase inhibitors |
WO2003068229A1 (en) * | 2002-02-11 | 2003-08-21 | Bayer Pharmaceuticals Corporation | Pyridine, quinoline, and isoquinoline n-oxides as kinase inhibitors |
US6541504B1 (en) * | 2002-04-03 | 2003-04-01 | Allergan Sales, Llc | (3Z)-3-(2,3-dihydro-1H-inden-1-ylidene)-1,3-dihydro-2H-indol-2-ones as kinase inhibitors |
TWI329112B (en) * | 2002-07-19 | 2010-08-21 | Bristol Myers Squibb Co | Novel inhibitors of kinases |
EP1543009A4 (en) * | 2002-08-02 | 2007-08-08 | Bristol Myers Squibb Co | Pyrrolotriazine KINASE INHIBITORS |
US6747025B1 (en) * | 2002-11-27 | 2004-06-08 | Allergan, Inc. | Kinase inhibitors for the treatment of disease |
JP2006514991A (ja) * | 2002-12-27 | 2006-05-18 | シエーリング アクチエンゲゼルシャフト | 新規医薬組合せ |
CA2530679A1 (en) * | 2003-06-30 | 2005-04-07 | Hif Bio, Inc. | Compounds for treating angiogenesis |
US7169802B2 (en) * | 2003-12-23 | 2007-01-30 | Cephalon, Inc. | Fused pyrrolocarbazoles |
-
2004
- 2004-07-07 SE SE0401790A patent/SE0401790D0/sv unknown
-
2005
- 2005-07-06 EP EP05757471A patent/EP1773309A1/en not_active Withdrawn
- 2005-07-06 WO PCT/SE2005/001116 patent/WO2006004545A1/en active Application Filing
-
2007
- 2007-01-05 US US11/620,275 patent/US20070213403A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20070213403A1 (en) | 2007-09-13 |
WO2006004545A1 (en) | 2006-01-12 |
EP1773309A1 (en) | 2007-04-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO2017019I2 (no) | Enzalutamid eller et farmasøytisk akseptabelt salt derav | |
CY1111729T1 (el) | Υπογλωσσιο επικαλυμμενο δισκιο | |
MX2008011978A (es) | Tratamiento del cancer de seno negativo al triple receptor. | |
EA200900202A1 (ru) | Селективные модуляторы андрогенного рецептора, их аналоги и производные и их использование | |
EA200870193A1 (ru) | Цитотоксические агенты, включающие новые производные томаймицина, и их терапевтическое применение | |
MX2009006704A (es) | Derivados de amina triciclicos como inhibidores de proteina de tirosina cinasa. | |
EA200870424A1 (ru) | Способы применения рецептора gpr119 для идентификации соединений, которые можно использовать для увеличения костной массы субъекта | |
UA96785C2 (uk) | Заміщені похідні оксиндолу та їх застосування як лігандів рецептора вазопресину | |
GT200800250A (es) | Arilimidazolonas y ariltriazolonas sustituidas como inhibidores de receptores de vasopresina | |
MXPA03011940A (es) | Ligandos del receptor de 5-ht- y sus usos. | |
MA32200B1 (fr) | Nouvelles formulations,comprimes comprenant de telles formulations, leur utilisation et leur procede de preparation | |
HK1108702A1 (en) | Ephb receptor-binding peptides ephb | |
CR10266A (es) | Software y metodos para la planeación de tratamientos dentales | |
CL2008001946A1 (es) | Compuestos derivados de imidazol, antagonistas de receptores ccr2, ccr3, ccr5; procedimiento de preparacion; y uso en el tratamiento de enfermedades vasculares perifericas. | |
MA32568B1 (fr) | Formulations pharmaceutiques contenant des ligands de recepteur de dopamine | |
DK1729753T3 (da) | Anvendelse af en NMDA-receptor-antagonist til behandling af tinnitus induceret ved kokleær excitotoksicitet | |
TN2009000371A1 (fr) | Composition pharmaceutique | |
MY151048A (en) | Use of flibanserin for the treatment of post-menopausal sexual desire disorders | |
MX2010006206A (es) | Derivados de oxindol substituidos por 5-halogeno y el uso de los mismos para el tratamiento de enfermedades dependientes de la vasopresina. | |
EA200700637A1 (ru) | Соли донепезила, подходящие для получения фармацевтических композиций | |
SE0501903L (sv) | Borföreningar användbara vid BNCT | |
DE602007006280D1 (de) | 1-phenethylpiperidinderivate und ihre verwendung als opioidrezeptor-liganden | |
NO20055207L (no) | Oralt farmasoytisk preparat for protonpumpeantagonister | |
EA200970849A1 (ru) | Трициклические производные изохинолина для лечения ожирения | |
AR048672A1 (es) | Tabletas de desintegracion que comprenden licarbazepina |